Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Employees

150

Sector

Biotechnology & Medical Research

Calendar

03-11 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
16/01/26	2.200 $	+5.77%	1,903,903
15/01/26	2.080 $	-3.26%	1,278,058
14/01/26	2.150 $	0.00%	948,937
13/01/26	2.150 $	-2.71%	1,406,476
12/01/26	2.210 $	+5.24%	3,239,299

Delayed Quote Nasdaq, January 16, 2026 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.200USD

Average target price

13.12USD

Spread / Average Target

+496.59%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Nasdaq Other stock markets 21:00:00 16/01/2026 GMT			5-day change	1st Jan Change
2.200 ^USD	+5.77%		+4.76%	+0.46%

01-12	Ind amendment clearance obtained for clinical manufacturing of Rese-Cel from Cabaletta Bio using Cellares' automated platforms	RE
01-12	Cabaletta Bio Receives FDA Clearance of an IND Amendment to Use Cellares' Cell Shuttle and Cell Q Platforms	CI

Capitalization	212M 182M 169M 158M 294M 19.24B 315M 1.95B 768M 9.16B 794M 778M 33.48B	P/E ratio 2025 *	-1.05x	P/E ratio 2026 *	-1.24x
Enterprise value	78.48M 67.41M 62.54M 58.43M 109M 7.13B 117M 723M 285M 3.4B 294M 288M 12.41B	EV / Sales 2025 *	-	EV / Sales 2026 *	-
Free-Float	96.9%	Yield 2025 *	-	Yield 2026 *	-

01-12	Ind amendment clearance obtained for clinical manufacturing of Rese-Cel from Cabaletta Bio using Cellares' automated platforms	RE
01-12	Cabaletta Bio Receives FDA Clearance of an IND Amendment to Use Cellares' Cell Shuttle and Cell Q Platforms	CI
12-22	Cabaletta Bio, Inc.(NasdaqGS:CABA) added to NASDAQ Biotechnology Index	CI
12-03	Cabaletta Bio, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 01:45 PM
11-10	Cabaletta Bio reports smaller-than-expected Q3 loss	RE
11-10	Cabaletta Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
27/10/25	Cabaletta Bio Shares Rise on Autoimmune-Disease Trial Results	DJ
27/10/25	Cabaletta Bio, Inc. Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025	CI
14/10/25	Cabaletta Bio, Inc. Announces the Appointment of Steve Gavel as Chief Commercial Officer, Effective from October 14, 2025	CI
09/10/25	Cabaletta Bio, Inc. Presents First Rese-cel Data with No Pre Conditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress	CI
09/10/25	Cabaletta Bio Inc reports new data from RESET-PV trial	RE
10/09/25	Certain Pre-funded Warrants of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 10-SEP-2025.	CI
10/09/25	Certain Stock Options of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 10-SEP-2025.	CI

11-10	Cabaletta Bio reports smaller-than-expected Q3 loss	RE
09/10/25	Cabaletta Bio Inc reports new data from RESET-PV trial	RE
11/06/25	Top Premarket Decliners	MT
16/05/25	UBS Adjusts Price Target on Cabaletta Bio to $6 From $7, Maintains Buy Rating	MT
01/04/25	UBS Adjusts Price Target on Cabaletta Bio to $7 From $10, Keeps Buy Rating	MT

Cabaletta Bio, Inc. Share Price

Equities

CABA

US12674W1099

Biotechnology & Medical Research

Valuation: Cabaletta Bio, Inc.

Chart: Cabaletta Bio, Inc.

Latest news: Cabaletta Bio, Inc.

Last Transcript: Cabaletta Bio, Inc.

Analysts' recommendations: Cabaletta Bio, Inc.

Press Releases: Cabaletta Bio, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Cabaletta Bio, Inc.

ETFs: Cabaletta Bio, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

01-12	Cabaletta Bio Announces 2026 Strategic Priorities	GL
01-12	IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms	BU
12-06	Cabaletta Bio : Corporate Presentation	PU
11-10	Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update	GL
11-04	Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December	GL

1 day	+5.77%
1 week	+4.76%
Current month	+0.46%
1 month	-8.71%
3 months	-22.81%
6 months	+31.74%
Current year	+0.46%

1 week	2.04	2.24
1 month	2	2.46
Current year	2	2.28
1 year	0.99	3.67
3 years	0.99	26.35
5 years	0.59	26.35
10 years	0.59	26.35

Manager	Title	Age	Since
Steven Nichtberger CEO	Chief Executive Officer	64	31/03/2017
Anup Marda DFI	Director of Finance/CFO	48	31/12/2018
Qing Sarah Yuan CTO	Chief Tech/Sci/R&D Officer	55	31/05/2024

Director	Title	Age	Since
Steven Nichtberger CHM	Chairman	64	31/03/2017
Mark Simon BRD	Director/Board Member	64	30/09/2018
Richard Henriques BRD	Director/Board Member	70	18/02/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CABALETTA BIO, INC.	+5.77%	+4.76%	-19.71%	-80.16%	212M
ARGENX SE	-2.91%	+0.24%	+6.15%	+90.12%	49.24B
WUXI APPTEC CO., LTD.	-1.83%	+3.34%	+93.19%	+8.09%	44.64B
INSMED INCORPORATED	+1.35%	-8.27%	+122.62%	+761.37%	34.43B
BIONTECH SE	+2.76%	+9.16%	-2.62%	-23.82%	27.35B
WUXI BIOLOGICS (CAYMAN) INC.	-4.83%	+0.75%	+102.46%	-46.22%	21.08B
GENMAB A/S	-6.50%	-5.50%	+35.30%	-24.56%	20.89B
AKESO, INC.	-3.06%	-6.98%	+96.15%	+150.64%	14.29B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-5.45%	-8.38%	+167.14%	-	14.17B
SUMMIT THERAPEUTICS INC.	-1.33%	-13.41%	-10.46%	+282.92%	13.14B
Average	-1.60%	-0.81%	+59.02%	+124.26%	23.94B
Weighted average by Cap.	-2.00%	-0.95%	+63.11%	+154.14%

	2025 *	2026 *
Net sales	-	-
Net income	-173M -149M -138M -129M -240M -15.72B -258M -1.59B -627M -7.48B -649M -635M -27.35B	-202M -174M -161M -150M -280M -18.36B -301M -1.86B -733M -8.74B -758M -742M -31.94B
Net Debt	-133M -114M -106M -99.26M -185M -12.11B -199M -1.23B -483M -5.77B -500M -490M -21.08B	-102M -87.51M -81.2M -75.87M -141M -9.26B -152M -938M -370M -4.41B -382M -374M -16.11B